PET imaging has become an essential part of radiation therapy for cancer patients. Leading off the issue are articles on clinical applications and technical aspects. Following those are reviews of the use of PET in the treatment for lung cancer, gynecologic malignancies, GI and pancreatic tumors, and brain tumors, lymphoma, and head and neck malignancies. The final article addresses advances in hybrid imaging in planning of radiation therapy.

This pocket book offers a succinct but comprehensive overview of the role of PET/CT in radiotherapy planning. Individual chapters are devoted to specific application of the technique to particular tumor types, including non-small cell lung, gastrointestinal, head and neck squamous cell, prostate, gynecological, and pediatric tumors. Helpful information is also presented on the practical implementation of PET/CT in routine oncological practice. Technical and logistical issues are discussed, and guidance provided on potential problems and pitfalls and available solutions. The book will be invaluable in assisting readers to exploit PET/CT’s ability to significantly improve delineation of tumor tissue through the addition of metabolic information to structural imaging data, thereby avoiding unnecessary radiation injury and associated complications while enhancing therapeutic effects and minimizing the risk of marginal recurrences. It is published within the Springer series Clinicians’ Guides to Radionuclide Hybrid Imaging, compiled under the auspices of the British Nuclear Medicine Society.

This issue, edited by Dr. Rakesh Kumar, reviews current clinical information in "PET Based Interventions." Articles will include: PET/CT in Radiofrequency Ablation; PET/CT Guided FNAC/Biopsy; PET/CT in Radiotherapy Planning; Dual Time Point Imaging; The Role of PET in Radiation Oncology; PET/CT in Individualization of Treatment (Personalized medicine); Ga68-DOTA-TOC PET/CT in targeted radionuclide therapy (Lu188 therapy for NET); Role of FDG PET/CT in Targeted Radionuclide Therapy of Endocrine Malignancies; Overview of Conventional Imaging Based Intervention in Clinical Practice; Special Techniques in PET/CT in Evaluating Genito-urinary Malignancies; and more!

PET/CT is an integral part of the evaluation of patients who have head and neck cancer. In this issue, the state of the art in PET/CT imaging is discussed. The issue starts with an overview of FDG-PET/CT, PET and MRI for normal anatomy, including pitfalls and artifacts. This topic is followed by a review of FDG-PET/CT for initial and subsequent therapy evaluation; progressing to PET and MRI. Other articles discuss SUV as a prognostic factor in head and neck squamous cell carcinoma, PET in head and neck cancer radiotherapy treatment planning, PET in decision making for neck dissection after radiation treatment, and newer methods for improving yield from FDG-PET imaging for accurate staging, determining tumor biology, and assessing prognosis. The issue focuses on some of the most cutting-edge applications, such as new tracers PET in head and neck squamous cell carcinoma (including FLT and hypoxia imaging). PET scans in thyroid cancer is also discussed.

This issue of PET Clinics focuses on Imaging in Gynecologic Oncology, and is edited by Drs. Drew Torigian and Domenico Rubello. Articles will include: The role of CT and MRI in gynecologic oncology; The utility of ultrasonography in gynecologic oncology; FDG-PET assessment of cervical cancer; FDG-PET assessment of ovarian cancer; FDG-PET assessment of other gynecologic cancers; The role of PET imaging in gynecologic radiation oncology; The utility of non-FDG PET in gynecologic oncology; Normal variants and pitfalls encountered in PET assessment of gynecologic malignancies; The role and future of quantitative imaging assessment in gynecologic oncology; Emerging molecular imaging techniques in gynecologic oncology; and more!

This issue of PET Clinics focuses on Lung Cancer, and is edited by Drs. Gang Cheng and Timothy Akhurst. Articles will include: FDG PET/CT for lung cancer staging; Lung neoplasms with low FDG avidity; FDG PET/CT evaluation of lung cancer in populations with high prevalence of granulomatous disease; Prognostic value of FDG PET/CT; Genomic characterization of lung cancer and its impact on the use and timing of PET in therapeutic response assessment; Treatment planning for radiation therapy; Future directions of PET imaging for lung cancer; PET for RT-planning in lung cancer; Genomic characterization of lung cancer and its impact on the use and timing of PET in therapeutic response assessment; and more!

In this issue of PET Clinics, guest editor Dr. Rathan M. Subramaniam brings his considerable expertise to the topic of Head and Neck Cancers. Top experts in the field provide important updates on planning, treatment, and individual head and neck cancers, with articles such as PET/CT: laryngeal and hypopharyngeal cancers; PET/CT: thyroid cancers; PET/CT: oral cavity and oropharyngeal cancers; and more. - Contains 10 relevant, practice-oriented topics including PET/CT: post-therapy follow-up in head and neck cancer; PET/CT: therapy response assessment in head and neck cancer; PET/CT: radiation therapy planning in head and neck cancer; PET/CT: nasopharyngeal cancers; and more. - Provides in-depth clinical reviews on head and neck cancers, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue, guest editors bring their considerable expertise to this important topic. - Contains 16 practice-oriented topics including fibroblast activation protein inhibitor (FAPI) PET imaging in pancreatic cancer; fibroblast activation protein inhibitor (FAPI) PET imaging in colorectal cancer; fibroblast activation protein inhibitor (FAPI) cardiac imaging; fibroblast activation protein inhibitor (FAPI) PET/CT in gastric cancer; and more. - Provides in-depth clinical reviews on fibroblast activation protein imaging, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

- Contains 12 relevant, practice-oriented topics including theragnostics trials; neuroendocrine tumors: diagnostics; prostate-specific membrane antigen: diagnostics; theragnostics: post-therapy imaging; fibroblast-activation-protein inhibitors (FAPI) theragnostics; and more. - Provides in-depth clinical reviews on theragnostics, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.In this issue of PET Clinics, guest editors Drs. Andrei Iagaru and Heather A. Jacene bring their considerable expertise to the topic of Theragnostics. Top experts in the field discuss neuroendocrine tumors: beta-labeled peptides; prostate-specific membrane antigen: interpretation criteria, standardized reporting and the use of artificial intelligence; prostate cancer (gastrin-releasing peptide receptor); selective internal radiation therapy; future directions in theragnostics; and more.

This issue provides a complete update on PET imaging of lymphoma, starting with a clinical assessment of lymphoma and the role of medical imaging. The role of structural imaging in lymphoma is then discussed. From a Nuclear Medicine perspective, FDG-PET in lymphoma is reviewed, as is the role of FDG-PET in pediatric lymphoma. Next, the role of non-FDG tracers in lymphoma is reviewed. Other articles cover the role of fMRI and optical imaging in lymphoma, the role of diffusion-weighted MRI in lymphoma, FDG-PET in personalization of therapy in patients with lymphoma, and PET and radiation oncology in lymphoma.